Skip to main content

Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice

ISSN: 03906078
27Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

The clinical data on the efficacy and toxicity of bortezomib as treatment for multiple myeloma patients are restricted to prospective phase II studies in expert myeloma centers. Here we report a multi-institutional analysis of the efficacy and toxicity of bortezomib in patients with relapsed or refractory multiple myeloma who were treated in community centers in a compassionate need program.

Cite

CITATION STYLE

APA

Wu, K. L., Van Wieringen, W., Vellenga, E., Zweegman, S., Lokhorst, H. M., & Sonneveld, P. (2005). Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica, 90(7), 996–997.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free